Lung cancer screening: where do we stand?
- PMID: 39193459
- PMCID: PMC11348916
- DOI: 10.1183/20734735.0190-2023
Lung cancer screening: where do we stand?
Abstract
Lung cancer screening (LCS) programmes have emerged over recent years around the world. LCS programmes present differences in delivery, inclusion criteria and resource allocation. On a national scale, only a few LCS programmes have been fully established, but more are anticipated to follow. Evidence has shown that, in combination with a low-dose chest computed tomography scan, smoking cessation should be offered as part of a LCS programme for improved patient outcomes. Promising tools in LCS include further refined risk prediction models, the use of biomarkers, artificial intelligence and radiomics. However, these tools require further study and clinical validation is required prior to routine implementation.
Copyright ©ERS 2024.
Conflict of interest statement
Conflict of interest: A. Frille reports receiving grants from “MetaRot program” fellowship from the Federal Ministry of Education and Research (BMBF), Germany (FKZ 01EO1501, IFB Adiposity Diseases): physician position, a junior research grant from the Medical Faculty, University of Leipzig (934100-012), a research grant from the “Mitteldeutsche Gesellschaft füür Pneumologie (MDGP) e.V.” (2018-MDGP-PA-002), and an unrestricted research grant by “Novartis Foundation”, outside the submitted work. F. Beyaz reports receiving a grant from the Dutch Cancer Foundation (KWF-grant number 14979), outside the submitted work. The remaining authors have nothing to disclose.
References
Publication types
LinkOut - more resources
Full Text Sources